Abstract

Trimethoprim (Trimopan - Berk; Ipral - Squibb; Syraprim - Wellcome) is now marketed here for the prophylaxis and treatment of urinary tract infection. Hitherto it has only been available either combined with sulphamethoxazole as co-trimoxazole (Septrin; Bactrim), which is particularly well established in the treatment of urinary tract infection, or with sulphadiazine as co-trimazine (Coptin), a combination we reviewed recently.¹ Trimethoprim has been available alone in Finland since 1973.